Ipsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-Oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Source: Business Insider
Ipsen and Biomunex Collaboration: Ipsen has entered into an exclusive global licensing agreement with Biomunex for BMX-502, a novel T cell engager targeting cancer cells, specifically engaging MAIT cells to attack the tumor antigen GPC3.
Financial Terms of the Agreement: Biomunex stands to gain up to $610 million from Ipsen, which includes upfront payments and milestones, along with tiered royalties on future sales as Ipsen takes charge of clinical development and commercialization.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
